These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16103876)

  • 21. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
    Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
    Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
    Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.
    Hurlin PJ; Foley KP; Ayer DE; Eisenman RN; Hanahan D; Arbeit JM
    Oncogene; 1995 Dec; 11(12):2487-501. PubMed ID: 8545105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
    D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
    J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
    Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
    Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C; Chen N; Sawadogo M
    Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mnt: a novel Max-interacting protein and Myc antagonist.
    Hurlin PJ; Qúeva C; Eisenman RN
    Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. hnRNP U interacts with the c-Myc-Max complex on the E-box promoter region inducing the ornithine decarboxylase gene.
    Matsuoka Y; Uehara N; Tsubura A
    Oncol Rep; 2009 Aug; 22(2):249-55. PubMed ID: 19578763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.
    Swarbrick A; Akerfeldt MC; Lee CS; Sergio CM; Caldon CE; Hunter LJ; Sutherland RL; Musgrove EA
    Oncogene; 2005 Jan; 24(3):381-9. PubMed ID: 15489884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of transcriptional repression by max homodimers.
    Yin X; Grove L; Prochownik EV
    Oncogene; 1998 May; 16(20):2629-37. PubMed ID: 9632139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO.
    Jiang G; Bi K; Tang T; Wang J; Zhang Y; Zhang W; Ren H; Bai H; Wang Y
    Int Immunopharmacol; 2006 Jul; 6(7):1204-13. PubMed ID: 16714225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
    Vervoorts J; Lüscher B
    Biol Chem; 1999 Sep; 380(9):1121-6. PubMed ID: 10543451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
    Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
    J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mxi1-SRalpha: a novel Mxi1 isoform with enhanced transcriptional repression potential.
    Dugast-Darzacq C; Pirity M; Blanck JK; Scherl A; Schreiber-Agus N
    Oncogene; 2004 Nov; 23(55):8887-99. PubMed ID: 15467743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repression by the Mad(Mxi1)-Sin3 complex.
    Schreiber-Agus N; DePinho RA
    Bioessays; 1998 Oct; 20(10):808-18. PubMed ID: 9819568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Myc-interacting proteins: a second Myc network emerges.
    Sakamuro D; Prendergast GC
    Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mad proteins contain a dominant transcription repression domain.
    Ayer DE; Laherty CD; Lawrence QA; Armstrong AP; Eisenman RN
    Mol Cell Biol; 1996 Oct; 16(10):5772-81. PubMed ID: 8816491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network.
    Yin XY; Gupta K; Han WP; Levitan ES; Prochownik EV
    Oncogene; 1999 Nov; 18(48):6621-34. PubMed ID: 10597267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential expression of the MAD family of transcriptional repressors during differentiation and development.
    Quéva C; Hurlin PJ; Foley KP; Eisenman RN
    Oncogene; 1998 Feb; 16(8):967-77. PubMed ID: 9519870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.